dyskinesias/fatigue

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 82 rezilta yo

[Therapeutic indications of symptomatology: fatigue, pain, abnormal movements and reeducation].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Multiple Sclerosis is a chronic progressive and handicapping pathology of the central nervous system. Despite the recent progress no curative molecule has fundamentally modified its prognosis. Within this context symptomatic treatments are inevitable. As part of this consensus conference we have

NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Tardive dyskinesia is a persistent movement disorder induced by chronic neuroleptic exposure. NBI-98854 is a novel, highly selective, vesicular monoamine transporter 2 inhibitor. We present results of a randomized, 6-week, double-blind, placebo-controlled, dose-titration study evaluating

The paroxysmal dyskinesias.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The clinical, pathophysiological and genetic features of some of the paroxysmal movement disorders are reviewed. Paroxysmal kinesigenic choreoathetosis/dyskinesias (PKC/PKD) is a condition in which brief and frequent dyskinetic attacks are provoked by sudden movement. PKC is more common in men and

A family with paroxysmal nonkinesigenic dyskinesia: genetic and treatment issues.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Paroxysmal nonkinesigenic dyskinesia is a condition characterized by attacks of sudden involuntary movements triggered by caffeine or alcohol intake, stress, or fatigue. The paroxysms are usually of the generalized type and may last up to an hour. Described here is a Polish family with this disorder

Late onset of atypical paroxysmal non-kinesigenic dyskinesia with remote history of Graves' disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Paroxysmal non-kinesigenic dyskinesia (PNKD) is a rare hyperkinetic movement disorder and falls under the category of paroxysmal movement disorders. In this condition, episodes are spontaneous, involuntary, and involve dystonic posturing with choreic and ballistic movements. Attacks last for minutes

Familial paroxysmal nonkinesigenic dyskinesia: clinical and genetic analysis of a Taiwanese family.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Paroxysmal nonkinesigenic dyskinesia (PNKD) is a rare disorder in autosomal dominant inheritance. The clinical features and genetic findings of PNKD, rarely described in the Asians, were mostly delineated from European families. The present study characterized the clinical and genetic findings of a

Paroxysmal non-kinesigenic dyskinesia due to a PNKD recurrent mutation: report of two Southern European families.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Paroxysmal non-kinesigenic dyskinesia (PNKD) is an autosomal dominant disorder characterized by attacks of dystonic or choreathetotic movements precipitated by stress, fatigue, coffee, alcohol or menstruation. In this report we present two families with PNKD of Southern European origin carrying a

Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Levodopa-induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once-daily ropinirole 24-hour prolonged-release (n = 104) in PD patients not optimally

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The metabotropic glutamate receptor 5-negative allosteric modulator dipraglurant reduces levodopa-induced dyskinesia in the MPTP-macaque model. The objective of this study was to assess the safety, tolerability (primary objective), and efficacy (secondary objective) of dipraglurant on

A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This phase 2 randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of the nicotinic acetylcholine receptor α7 agonist AQW051 in patients with Parkinson's disease and levodopa-induced dyskinesia. Patients with idiopathic Parkinson's disease and moderate to severe

Paroxysmal non-kinesigenic dyskinesia caused by the mutation of MR-1 in a large Polish kindred.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Paroxysmal non-kinesigenic dyskinesia (PNKD) is a clinical syndrome of sudden involuntary movements, mostly of dystonic type, which may be triggered by alcohol or coffee intake, stress and fatigue. The attacks of PNKD may consist of various combinations of dystonia, chorea, athetosis and balism.

Risk Factors of Fatigue in Idiopathic Parkinson's Disease in a Polish Population.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Introduction. Fatigue syndrome is one of the nonmotor symptoms in Parkinson's disease (PD). The aim of the study was assessment of prevalence of fatigue syndrome in PD and answering the question what are the independent risk factors connected with intensity of fatigue in PD. Methods. 114 patients

[Fatigue and weight loss in Parkinson's disease].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Fatigue is a common, under recognized, and poorly understood nonmotor symptom in Parkinson's disease (PD). Fatigue frequently presents early in PD, and its prevalence increases with disease progression, affecting up to 60% of patients. Fatigue has a negative impact on quality of life. Fatigue is

Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE The objective of this systematic review was to describe the efficacy, tolerability, and safety of valbenazine for the treatment of tardive dyskinesia (TD). METHODS The pivotal registration trials were accessed by querying http://www.ncbi.nlm.nih.gov/pubmed/ and

Towards an understanding of fatigue in Parkinson disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To gain an improved understanding of fatigue in Parkinson disease (PD) by exploring possible predictors among a wide range of motor and non-motor aspects of PD. METHODS 118 consecutive PD patients (54% men; mean age 64 years) were assessed regarding fatigue, demographics and a range of

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye